Wednesday, February 23, 2011

Smith & Nephew Medical Device Company Intelligence Report


Smith & Nephew Medical Device Company Intelligence Report

  • Orthopaedics – Produces orthopaedics reconstruction implants including hip, knee and shoulder joints, as well as ancillary products such as bone cement and mixing systems used in cemented reconstruction joint surgery; orthopaedic trauma fixation products consisting of internal and external devices and other products, including shoulder fixation and orthobiological materials used in the stabilisation of severe fractures and deformity correction procedures; and clinical therapies products such as bone growth stimulation, joint fluid therapies and out-patient pain management products. Included within the Orthopaedics segment are S&N’s biologics activities, which comprise research and development projects representing all three global business units. In April 2010, S&N sold its Interventional Spine Pain Management assets to NeuroTherm.
  • Endoscopy – Focusing on the minimally-invasive sector of the endoscopy market, this business offers specialised devices and fixation systems to repair damaged tissue; fluid management equipment for surgical access; digital cameras, digital image capture, scopes, light sources and monitors to assist with visualisation; and radiofrequency wands, electromechanical and mechanical blades, and hand instruments for resecting damaged tissue.
  • Advanced Wound Management – Provides a range of products from initial wound bed preparation through to full wound closure.
S&N concluded two key acquisitions in 2007. BlueSky Medical Group added a new line of products to S&N’s portfolio: these are focused on the nascent market of negative pressure wound therapy (NPWT), an area that S&N believes offers greatest growth opportunities in the coming years. Plus Orthopedics Holdings has significantly bolstered S&N’s share of the global market for orthopaedics products and solutions. Indeed, S&N now claims to be the fourth-largest global orthopaedics reconstruction company.
The S&N group operates in 32 countries and has a global workforce of more than 9,700 employees. In 2009, the company generated net income of US$472 million on revenue of US$3,772 million.
In January 2011, it was widely reported that Johnson & Johnson’s hotly contested battle with Zimmer in the worldwide orthopaedics markets had led to a takeover approach for S&N, although this was rebutted by the latter in a formal statement. When the J&J rumour died down, it was time for another suitor to return from a hiatus – a possible offer from private equity owned-Biomet. S&N almost merged with Biomet a few years ago but was outbid by a private equity consortium. Medtronic is another party that has been named as a potential suitor, although it seems to be more focused on expanding its cardiovascular business rather than achieving sizeable growth in orthopaedics.
Buy Now: Market Research

Related Reports